SCHEMBL7870895

SCHEMBL7870895

CCCCCCCCCCCC(CCCCO)OC(CCCCO)CCCCCCCCCCC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.59
ALDH1A1 P00352 2/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
HSD17B10 Q99714 1/20 0.59
TSHR P16473 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.55
PTPN1 P18031 1/20 0.42
CYP2D6 P10635 2/20 0.41
MAPT P10636 2/20 0.41
HTT P42858 2/20 0.41
SPHK1 Q9NYA1 1/20 0.41
GMNN O75496 1/20 0.41
POLB P06746 1/20 0.41
THPO P40225 1/20 0.41
MTOR P42345 1/20 0.41
BLM P54132 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10893740 1.00 LMNA (0.59) LMNAALDH1A1MEN1KMT2AHSD17B10
SCHEMBL8830679 1.00 LMNA (0.59) LMNAALDH1A1MEN1KMT2AHSD17B10
SCHEMBL7872778 1.00 LMNA (0.59) LMNAALDH1A1MEN1KMT2AHSD17B10
SCHEMBL7875788 0.95 LMNA (0.52) LMNAALDH1A1MEN1KMT2AHSD17B10
SCHEMBL7863756 0.95 LMNA (0.52) LMNAALDH1A1MEN1KMT2AHSD17B10
SCHEMBL7869209 0.95 LMNA (0.52) LMNAALDH1A1MEN1KMT2AHSD17B10
SCHEMBL6275482 0.95 LMNA (0.52) LMNAALDH1A1MEN1KMT2AHSD17B10
SCHEMBL1705524 0.95 LMNA (0.52) LMNAALDH1A1MEN1KMT2AHSD17B10
SCHEMBL1705822 0.95 LMNA (0.52) LMNAALDH1A1MEN1KMT2AHSD17B10
SCHEMBL18342526 0.93 LMNA (0.50) LMNAALDH1A1MEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0483105-B2 Solid drug-delivery devices employing fatty acid esters or fatty alcohol ethers of alkanediols as percutaneous absorption enhancers ORTHO MCNEIL PHARM INC (US) 2001-01-17 EP disclosed
EP-0272987-B1 RESILIENT TRANSDERMAL DRUG-DELIVERY DEVICE AND COMPOSITIONS AND DEVICES EMPLOYING FATTY ACID ESTERS/ETHERS OR ALKANEDIOLS AS PERCUTANEOUS ABSORPTION ENHANCERS CYGNUS THERAPEUTIC SYSTEMS (US) 1993-03-24 EP disclosed
EP-0272918-B1 DIFFUSION MATRIX FOR TRANSDERMAL DRUG ADMINISTRATION AND TRANSDERMAL DRUG DELIVERY DEVICES INCLUDING SAME CYGNUS THERAPEUTIC SYSTEMS (US) 1992-07-15 EP disclosed
EP-0483105-A1 Solid drug-delivery devices employing fatty acid esters or fatty alcohol ethers of alkanediols as percutaneous absorption enhancers CYGNUS THERAPEUTIC SYSTEMS (US) 1992-04-29 EP disclosed
US-5006342-A Resilient transdermal drug delivery device CYGNUS CORPORATION (US) 1991-04-09 US disclosed
US-4911916-A Diffusion matrix for transdermal drug administration and transdermal drug delivery devices including same CYGNUS RESEARCH CORPORATION (US) 1990-03-27 US disclosed
US-4906463-A Transdermal drug-delivery composition CYGNUS RESEARCH CORPORATION (US) 1990-03-06 US disclosed
EP-0272987-A2 Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers or alkanediols as percutaneous absorption enhancers CYGNUS THERAPEUTIC SYSTEMS (US) 1988-06-29 EP disclosed
EP-0272918-A2 Diffusion matrix for transdermal drug administration and transdermal drug delivery devices including same CYGNUS THERAPEUTIC SYSTEMS (US) 1988-06-29 EP disclosed